Grey’s Anatomy recap: ‘What’s Inside’ – EW.com

Have you stopped crying from last week? Me neither. Neither have your regular recappers, who are out this week, but in their stead, I take onGreys Anatomy with you Youre in trusted hands because I pick you, I choose you, I love you. I dont need to loveGreys, but I want to, and sometimes I cant think about the bigger picture because Ive lost my shoe. But well all pull it together this week because in the wake of losing her mother, Maggie needs us. Shes about to join a sacredGreys club.

Its finally time for the last sister to become twisted. After losing her mom last week, we open with Maggie at her mothers grave a concept foreign to Mer and Amelia because you know, dark and twisty hall of fame. Amelia has her oxycodone background and Meredith has, well, everything. But after the graveyard, its time for Maggies first day back.

Riggs catches Arizona and Mennick carpooling in together, which is what it is. We turn a blind eye to Mennick because there are bigger fish to fry. Example: Arizonas pregnant patient, whom she placed a shunt in last week. No matter how much Arizona wants to make a point that she and Mennick werent justcarpooling in together, her patients heart surgery is more complicated than matters of the bedroom. Maggie hears about it and immediately wants in because thats what surgeonsdo when tragedy happens: cut stuff. But this is Dr. Herman fetal surgery-level serious, and not everyone is so sure shes ready for it. And when the patient overhears that maybe Maggie shouldnt be taking it on, they want answers.

Stephanie is stuck with Cross, and honestly, she has no time for it. Its what makes Stephanie wonderful. She calls in DeLuca to try to shame Cross into getting out of bed, but when he protests that hes actually sick, Stephanie goes to step two: rectal exam. But after landing himself in an MRI, it does appear that Cross has a point after all. He has diverticulitis, an annoyed Stephanie is going to operate, and you can only think with a case so simple, thiscant go well, right?

Poor Meredith has little knowledge of when someone is okay or not okay. Its a symptom of being kind of twisted your whole life. And when everyone believes that maybe Maggie needs a break, Meredith argues otherwise because she operated through a miscarriage remember? Yikes. But after enough pushing, Amelia and Meredith try to question Maggie on whether or not shes ready, and she doesnt love it at all because today is her day. Her First Day Back From Dead Mom Day, and theyre not there for her, yall! But Maggie goes into surgery with Arizona, who asks her one last time if shes okay because this is tiny humans, and shehas to be on for the tiny humans. But after removing the tumor like a complete boss, Maggie freezes when the baby starts coding. What needs to be done? Who knows Maggie isnt talking.

Read the rest here:
Grey's Anatomy recap: 'What's Inside' - EW.com

Professor Sends Out Survey to Gauge Interest in Neuroscience … – The Heights

John Christianson, a neuroscientist and the Gianinno Family Sesquicentennial Assistant Professor of Psychology at Boston College, emailed a brief survey to psychology students on Monday, March 27, and received roughly 250 responses out of the nearly 1,000 students emailed.

The survey asked students to rate their agreement or disagreement with various statements, such as, A minor in neuroscience would satisfy my academic goals, and, Assuming I would still graduate on time, if BC offered a neuroscience B.S., I would change to that major today.

For now, Christianson wont share results of his survey, which was sent to psychology majors and any student who has taken a psychology class.

The goal of the survey was to quantify the opinions of our current students so that we can use that as part of a comprehensive self-study, Christianson said in an interview. After a satisfactory response rate, the survey was closed on Tuesday, April 4.

That self-study, which is an attempt to examine how a neuroscience program at BC might best be created, if at all, is still ongoing. At some point, survey results will be made public, and may be featured, sometime in the near future, in a white paper or an executive summary of the self-study linked to the psychology departments website.

Were also evaluating our department from the faculty levelwhat areas we want to strengthen, how these align with trends in the field, and how what we could do as a neuroscience program compares to what other excellent neuroscience programs are doing [at other universities], Christianson said.

Among the 40 highest-ranked national universities in the United States, Boston College is ranked 31st. Of those 40 institutions, 18 offer a major in neuroscience, according to U.S. News and World Report.

What we cant assess is how many people didnt come to BC because we dont have a major in neuroscience, Christianson cautioned.

Neuroscience, an interdisciplinary field which consists of the study of the nervous system, is a field in which BCs department of psychology, which studies the human mind and its intersection with human behavior, has considerable academic strength.

Approximately seven years ago, a group of faculty from various disciplines gave a presentation to the BC administration concerning the possibility of launching a new, interdisciplinary neuroscience major. Despite the presentations positive reception, the major was not created.

Instead, a B.S. in psychology was created and first awarded in 2012. It features largely the same curriculum that was contained in the 2010 presentation, though it lacks some courses from other disciplines, such as biology, chemistry, and physics, which are often part of neuroscience programs.

At the time, some felt that BC had insufficient resources to offer a competitive neuroscience programonly seven professors in the psychology department were neuroscientists. Since then, efforts toward creating a neuroscience major have languished due to a lack of momentum.

Since then, BC has hired 25 new professors, across several departments, with interests in neuroscienceas a result of this recent growth, a larger variety of neuroscience courses and research opportunities are now available, and the B.S. track has become even stronger in neuroscience. Some of those hires were replacements to professors who departed, but most are additional positions.

We have what feels [to students] like a disconnect between what we offer in the psychology department, in terms of courses, and what we call it, Christianson said.

The psychology department offers two degreesa Bachelor of Arts and a Bachelor of Sciencein psychology. The B.A. track gives students extensive choice in what they can study, and a breadth of exposure to a wide range of topics, while the B.S. track emphasizes upper-level courses on behavioral and cognitive neuroscienceit was intended to enable students to go on to work successfully in the neuroscience field.

Today, 11 of the 24 psychology faculty members at BC are neuroscientists, who publish their research in neuroscience journals and teach a number of classes in the field. The course load required for a psychology B.S. is roughly comparable to that of a neuroscience major at many universities with prestigious programs in that field.

We could do something right now, which would be just to change the name [of the B.S. track to a major in neuroscience], and really do nothing elseand that would really be in line with a lot of whats out therebut that might not be the best thing for BC, Christianson said.

Christiansons self-study aims to answer difficult questions about a possible neuroscience program and its place at BChow to provide recognition to students earning the B.S. degree for their neuroscience-heavy coursework, how to shape a program that fits within the Universitys mission to approach curricula holistically, how it might interlock with the Core Curriculum, and how such a program might compare to those of other universities.

The breadth of the field of neuroscience is such that having a psychology degree is not unusual among those working in the field.

We may put too much stock in the name of our undergraduate degrees, Christianson said. For example, English or economics majors can go to graduate school in neuroscience if theyve taken the right set of background courses.

Since neuroscience is an interdisciplinary fielddrawing upon psychology, biology, and computer science, among other disciplinesextensive collaboration among BC departments would be needed to create such a program, and BCs lack of a medical school or an engineering program poses a challenge.

Provost and Dean of Faculties David Quigley said in an email that new interdisciplinary majors require a high level of support from existing departments.

The primary costs [of a new major] are faculty to teach in the program and administrative support for students and faculty, Quigley said. Additional costs include research expenses as well as funds directed toward lectures and seminars by visiting scholars.

Neuroscience research, in particular, requires expensive instruments, extensive work space, and intensive collaboration among faculty working in close proximity to one another, and, ideally, a wet lab allowing students to engage in hands-on study and faculty to conduct research. Currently, the psychology department does not have such a laboratory.

By consistently hiring neuroscientists over the past decade, the psychology departmentand ultimately the University, which approves new hireshas demonstrated a commitment to growing the psychology departments strength in neuroscience, but commitments by other departments are also critical.

Those other departments, such as biology, chemistry, physics, and computer science, do not have a significant neuroscience presenceBCs relatively smaller size, compared to universities of comparable prestige, has led these departments to specialize in subject areas in which they have considerable expertise. Those areas, generally, have not included neuroscience.

In addition, the sub-fields of molecular, developmental, and computational neuroscience, which are critical components of a strong neuroscience program, require strength in biology and computer science. Many of the relevant computer science classes at BC are currently operating at close to full capacity.

When asked if students prospects in employment or acceptance to graduate schools were harmed by not having a neuroscience major on their resumes, Christianson was skeptical.

I think [students] think it does, [but] Im not surehaving a degree from Boston College means a ton, and the name of the university carries, probably, more clout than the name of the department, Christianson said. I think if [students] are really interested in neuroscience, they have to explain themselves [to potential employers].

Grace Elliott, MCAS 18, who is currently pursuing a B.S. in psychology, agrees.

I have found that I have to qualify my psych degree by explaining that I have a focus in neuroscience and take a lot of bio-heavy classes, Elliott said. It would be helpful to specify what exactly I try to study.

While Christianson is still currently in what he called an early plan-generation phase of self-study, when asked what hed like to see in five years, he expressed a personal hope that BC will offer a major in neuroscience, and that there would be a commitment for the University to become a leader in the field.

If students who are are reading this [article], or faculty, or anyone want to weigh in on this [question], now is the time to have their voice heard, Christianson said. We want to be as inclusive as possible to students, faculty, or any other interested parties.

Featured Image Courtesy of the Association for Talent Developement

Original post:
Professor Sends Out Survey to Gauge Interest in Neuroscience ... - The Heights

Neuroscience student wins thesis contest – The Kingston Whig-Standard

WADE MORRIS

The Whig-Standard

KINGSTON - Queen's University neuroscience student Victoria Donovan will represent the university at a provincial competition after being declared the winner of Queen's fifth annual 3 Minute Thesis contest last week.

Donovan and 10 other Queen's students competed against each other, giving presentations of their thesis projects in less than three minutes, with only one slide and no props.

The judging criteria was based on comprehension, engagement and communication.

The panel of judges -- Queen's principal Daniel Woolf, chancellor Jim Leech, CEO of 8020Info Robert Wood, media coach J.C. Kenny and fundraiser Denise Cumming -- selected Donovan's presentation, titled "Lie Low, Stay Alive," as the winner based on that criteria.

Donovan's presentation explored how she was aiming to understand traumatic brain injuries from an evolutionary perspective.

"Doing so could not only improve future treatment for patients but also minimize the number of mammals required for TBI research," Donovan said.

Donovan could not use props, but thought of a different way to captivate the audience: she asked everyone to make a fist with their hand, putting their thumb on the inside of their fist.

The thumb, she explained, represented the evolutionary old part of a brain that is present in most organisms. The fingers wrapped around the thumb represented the evolutionary part of the brain present only in higher-order organisms as it functions in cognition, language skills and fine motor skills.

"A big difference between the two regions is that the higher brain is less resilient to trauma," Donovan explained.

After Donovan was awarded first place -- with a $1,000 cheque attached -- she thanked those who supported her, including her family, friends and even her cats.

"Despite the fact that they don't have a long attention span, I really appreciate their support," she joked.

Host Bill Welychka said after her presentation that she'd used her cats as an audience in front of which she practised. Her next audience will perhaps be more intimidating: Donovan will represent Queen's at the provincial edition of 3 Minute Thesis, where winners from different schools in the province will compete against each other. If Donovan wins, she'll then compete in a national 3 Minute Thesis competition.

"I'm excited to represent Queen's," Donovan said. "I've been at Queen's for going on six years now and I definitely don't regret a minute of it."

Donovan also won People's Choice, which was chosen by the audience.

Queen's computing student Amani Ibrahim was the runner-up, receiving $500 for her presentation titled "Moving Surgical Design Outside the Operating Room."

Queen's has a history of making its mark at the provincial and national levels of the competition.

In 2015, Chenman Yin of Queen's won People's Choice at the national level, and last year Anastasia Shavrova of Queen's placed third at the provincial level.

Donovan will compete against other 3 Minute Thesis winners from the province on April 12 at the University of Waterloo.

Read the original:
Neuroscience student wins thesis contest - The Kingston Whig-Standard

This Week in Neuroscience News – 4/7/17 – ReliaWire

In our week-end roundup of neuroscience news covering various developments in brain science, we look at electrical spinal cord stimulation, deconstructing behavioral neuropharmacology, and other areas.

Earlier in the week, Mayo Clinic researchers reported they used electrical stimulation on the spinal cord and intense physical therapy to help a man intentionally move his paralyzed legs, stand and make steplike motions for the first time in three years.

The patient underwent surgery to implant an electrode in the epidural space near the spinal cord below the injured area. The electrode is connected to a computer-controlled device under the skin in the patients abdomen. This device, for which Mayo Clinic received permission from the U.S. Food and Drug Administration for off-label use, sends electrical current to the spinal cord, enabling the patient to create movement. (Peter J. Grahn et al. Enabling Task-Specific Volitional Motor Functions via Spinal Cord Neuromodulation in a Human With Paraplegia, Mayo Clinic Proceedings)

Researchers at Duke University and the Howard Hughes Medical Institute have developed a way to deliver drugs to specific types of neurons in the brain.

The approach could eventually provide a platform whereby the mechanism of action for widely psychiatric prescribed drugs can be examined with cellular specificity in animal models of several disorders. Such studies could inform new translational strategies by advancing non-obvious drug combinations. (New Method Targets Neuropsychiatric Drugs To Genetically Specified Cells)

In more neurostimulation news, thalamic deep brain stimulation, a surgical technique that sends electrical impulses to a specific area of the brain, reduces the tics experienced by young adults with severe cases of Tourette syndrome, according to a new study from NYU Langone Medical Center published April 7 in the Journal of Neurosurgery.

The deep brain stimulation involves a multi-stage procedure. First, two electrodes are inserted the medial thalamus, part of the brain circuit that functions abnormally in Tourettes. During a second surgery the following day or a few days later, a pacemaker-like device called a neurostimulator is connected to the electrodes to emit electrical impulses into the medial thalamus. These impulses are adjusted during a series of follow-up outpatient visits to find the combination of settings that best control symptoms.

To determine the effectiveness of the procedure, the researchers measured the severity of tics before and after surgery in 13 patients. They found that the severity of tics decreased on average 37 percent from the time of the operations to the first follow-up visit. At their latest visit, patients tic scores decreased by an average of 50 percent.

University of Michigan researchers used PET scans of the brain in a small study to demonstrate that dopamine falls and fluctuates at different times during migraine headaches. During an attack, the 8 migraine patients studied showed dopamine levels that fell significantly, they found.

Migraine was also the subject of focus in a study from researchers at the University of Toronto who found that generalized anxiety disorder is much more common among adults who have migraines than those without migraine.

An earlier study in 2008 made a link between social anxiety disorder and altered dopamine uptake activity in the striatum. Another 2008 study in Nature Neuroscience linked anxiety, emotional processing in the amygdala, and dopamine storage capacity.

Interestingly, the University of Michigan study found that men with migraine had almost double the odds of generalized anxiety disorder compared with women with migraine.

This was a surprising finding because in the general population, women are more likely than men to develop generalized anxiety disorder. Our results may be due to the fact that men are less likely than women to take medication to treat their migraine and therefore the disorder may be more painful and less controllable, which could result in anxiety

said co-author Senyo Agbeyaka, a recently graduated MSW student.

Whats more, migraineurs who did not have a confidant had five times the odds of generalized anxiety disorder compared to those with at least one person to confide in; with social support being shown to play an important protective role in the mental health consequences of other chronic pain disorders.

Elsewhere, researchers warned regulators of the need to monitor and control the use of ketamine for the treatment of depression. In the study, published in Lancet Psychiatry, Oxford University specialists said patients treatment should be in specialist centers and formally tracked in national or international registries. Johnson & Johnson is currently developing an intranasal form of the drug, esketamine. Early results have been promising enough for Food and Drug Administration officials to award esketamine breakthrough status to speed its progress through regulatory hurdles.

Image: Mayo Clinic

See the rest here:
This Week in Neuroscience News - 4/7/17 - ReliaWire

Cancer Genetics, Inc. is Selected by eFFECTOR Therapeutics to Provide Biomarker Discovery and Development … – GlobeNewswire (press release)

April 10, 2017 07:00 ET | Source: Cancer Genetics, Inc.

RUTHERFORD, N.J. and SAN DIEGO, April 10, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) (CGI or The Company), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today that it has been chosen by eFFECTOR Therapeutics, Inc., a biopharmaceutical company developing selective translation regulators for the treatment of cancer, to provide clinical biomarker services for eFFECTORs lead product candidate eFT508. The two companies will work together on eFFECTORs strategies to implement studies aiding in biomarker discovery and development, including immuno-oncology biomarkers, allowing further optimization of eFT508 development as a single agent and in drug combinations.

eFT508 is a novel, potent and highly selective oral small molecule inhibitor of MNK1 and 2 (MAP kinase-interacting kinase 1 and 2). MNK1 and MNK2 integrate signals from several oncogenic and immune signaling pathways, including RAS, Toll-like receptors and the T-cell receptor, by phosphorylating eukaryotic initiation factor 4E (eIF4E) and other key effector proteins. Phosphorylation of these RNA-binding proteins by MNK1 and MNK2 selectively regulates the stability and translation of a subset of cellular mRNA that control cell signaling within and between tumor and immune cells, the tumor microenvironment and immune cell function. In preclinical studies, eFT508 has demonstrated activity in multiple tumor models as well as establishment of anti-tumor immune memory.

eFT508 is currently in Phase 1/2 clinical development targeting multiple solid tumors and lymphoma, and has been recently granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of diffuse large B-cell lymphoma (DLBCL). eFFECTOR has designed a biomarker strategy to demonstrate target engagement, inform patient selection and validate the immunological mechanism of action of the drug. These biomarkers will allow for the determination of both circulating and tumor infiltrating immune cell types and their activation state in patients before and after treatment with eFT508 across the ongoing clinical program.

Our collaboration with CGI will allow us to measure several important biomarkers that may reflect eFT508s mechanism of action, as well as identify responsive patient populations, said Kevin Webster, Ph.D., Senior Vice President of eFFECTOR Therapeutics. This will be particularly useful for eFT508, which acts both on tumor cell intrinsic signaling and on extrinsic signaling within tumor infiltrating immune cells, leading to induction of anti-tumor immunity in addition to direct anti-tumor activity.

Cancer Genetics is currently supporting over 125 clinical trials and studies globally with 40 focused on immune therapies. Panna Sharma, CEO and President of CGI commented, The ability to partner with innovative therapeutic companies and help with the critical work across critical topics such as biomarker discovery, identification of immune markers, and immunological mechanisms of action of the drug is a testament to the value and depth of our capabilities and portfolio. Our expanding customer base of highly innovative companies, such as eFFECTOR, highlights our value proposition to the biopharma community. We are very motivated by this opportunity and ready to empower eFFECTOR to achieve important clinical milestones through the use of CGIs extensive oncology-focused menu and biomarker development expertise.

About eFFECTOR Therapeutics eFFECTOR Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of selective translation regulators as a new class of small molecule therapeutics for cancer. The companys investigational compounds are designed to restore translational control to halt underlying disease mechanisms while preserving healthy physiological processes. eFFECTORs most advanced program focuses on the development of eFT508. The company has additional selective translation regulator programs currently in discovery and development. For more information visit http://www.effector.com.

About Cancer Genetics, Inc. Cancer Genetics, Inc. is an emerging leader in enabling precision medicine for oncology through the use of molecular markers and information. CGI is developing a global footprint with locations in the US, India and China. It has established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.

The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State.

For more information, please visit or follow us:

Internet:www.cancergenetics.com Twitter:@Cancer_Genetics Facebook:www.facebook.com/CancerGenetics

Forward-Looking Statements: This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in revenues, margins, research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. tests and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements.

Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the discovery, development and/or commercialization of potential therapies or products, risks of cancellation of customer contracts or discontinuance of trials, risks that anticipated benefits from acquisitions will not be realized, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Cancer Genetics, Inc. Form 10-K for the year ended December 31, 2016 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics, Inc. disclaims any obligation to update these forward-looking statements.

Related Articles

Rutherford, New Jersey, UNITED STATES

http://cancergenetics.com

Cancer Genetics, Inc. Logo

LOGO URL | Copy the link below

Formats available:

See the rest here:
Cancer Genetics, Inc. is Selected by eFFECTOR Therapeutics to Provide Biomarker Discovery and Development ... - GlobeNewswire (press release)

Too Much Information? FDA Clears 23AndMe to Sell Home Genetic Tests for Alzheimer’s and Parkinson’s – Scientific American

Genetic testing company 23AndMe is back with a controversial new offering, after the U.S. Food and Drug Administration on Thursday green-lighted the companys request to market a fresh batch of direct-to-consumer tests. Soon, with a simple saliva swab dropped in the mail, customers will be able to get answers about their genetic risk for developing 10 maladiesincluding Parkinsons disease and late-onset Alzheimers.

The FDA approval will likely reignite a long-simmering debate about when and how such tests should be used. Even when there are strong links between certain gene variants and medical conditions, genetic information often remains difficult to interpret. It must be balanced against other factors including health status, lifestyle and environmental influences, which could sharpen or weaken risk. If disease risk news is delivered at homewithout a genetic counselor or doctor on hand to offer contextmany geneticists fear it can lead to unnecessary stress, confusion and misunderstandings.

Against that backdrop, the FDAs decision came with caveats: Results obtained from the tests should not be used for diagnosis or to inform treatment decisions, the agency said in a statement. It added that false positive and false negative findings are possible.

But geneticist Michael Watson, executive director of the American College of Medical Genetics and Genomics, thinks consumers will have trouble making such distinctions and says he doubts people will view them as a mere novelty. Watson also worries 23AndMes wares may create other problems: Follow-up testing for some of these conditions may be quite pricey, he says, and insurance companies might not cover that cost if a person has no symptoms. He also notes that some of the conditions involved may have no proved treatments, leaving consumers with major concernsand few options to address them, aside from steps like making some lifestyle changes.

The makeup of 23AndMes reports to consumers is still being finalized, but the company says it does not expect to grade or rank a persons risk of developing any of the 10 conditions approved for analysis. Instead it will simply report a person has a gene variant associated with any of the maladies and is at an increased risk, the company told Scientific American.

The FDA decision may significantly widen the companys market and top off a years-long debate about what sort of genetic information should be available to consumers without professional medical oversight. After the FDAs 2013 decision to stop 23AndMe from sharing data about disease risk with its customers, the company was still able to offer them information about their genetic ancestry. It has also been selling consumer tests for genes that would indicate whether people are carriers for more than 30 heritable conditions, including cystic fibrosis and Tay-Sachs disease.

This month 23AndMe plans to release its first set of genetic health-risk reports for late-onset Alzheimers disease, Parkinsons disease, hereditary thrombophilia (a blood-clotting disorder), alpha 1-antitrypsin deficiency (a condition that raises the risk of lung and liver disease), and a new carrier status report for Gauchers disease (an organ and tissue disorder). Reports for other tests will follow, the company says.

In considering whether to approve the tests, the FDA says it reviewed studies that demonstrated the 23AndMe procedures correctly and consistently identified variants associated with the 10 conditions. Further data from peer-reviewed scientific literature demonstrated the links between these gene variants and conditions, and supported the underlying science.

The FDA also announced on Thursday that it plans to offer the company exemptions for similar genetic tests in the future, without requiring them to be submitted for premarket review. That decision could leave the door open to offering tests for other conditions that have questionable reproducibility, says Jim Evans, a genetics and medicine professor at the University of North Carolina School of Medicine.

Read the original post:
Too Much Information? FDA Clears 23AndMe to Sell Home Genetic Tests for Alzheimer's and Parkinson's - Scientific American

Why people do not volunteer – Progress Index

More than 60 volunteers contributed to successful Farm Day in Prince George

We asked our research team to find out why so many people do not volunteer and the resounding response was, Because they were not asked.

Willie Bresko is a farmer in Prince George County, Virginia, who has volunteered his time and his farm with Virginia Cooperative Extension/Prince George 4-H for over a decade. I asked him why and he replied, Because I was asked.

This past week, Willie hosted our thirteenth annual Farm Day as he has done every year for the past 13 years. Second-graders from all the elementary schools in Prince George County about 450 students came to Willies farm last Tuesday to discover some of the major roles that agriculture plays in our daily lives.

As one of the teachers was leading her students back to the school bus, she told me, I have been to all of them (Farm Day events) this one was the best one ever!

The volunteers are the ones I have to thank for this great report.Volunteers like Willie Bresko who volunteered because he was asked.

Over 60 volunteers from Prince George Master Gardeners, Prince George 4-H, Prince George Farm Bureau, Virginia State University, Prince George Public Schools, Natural Resource Conservation Service, James River Soil and Water Conservation Service, Prince George Fire and EMS, Farm Bureau Womens Committee and a host of local citizens gave their time, energy and resources to make Farm Day a success.

Volunteers helped to provide eight learning stations: dairy cows, embryology, aquaculture, farm animals, field crops, vegetables, farm economics and soils. Volunteers provided lunch, served as mentors/guides, transported students, and an array of other tasks necessary to make the event a smashing success.

Director of Virginia Cooperative Extension Edwin Jones said, "The tremendous difference Virginia Cooperative Extension has made in the lives of Virginians over the past 100 years has been due in large measure to the contributions of the many dedicated and tireless volunteers."

Over 30,000 volunteers provided approximately 966,000 hours of service with Virginia Cooperative Extension in a single year. In that same year, 13,000 adult and youth volunteers served more than 185,000 youth ages 5 to 18 in hands-on educational programs designed to build leadership, citizenship, and life skills through Virginia 4-H.

Our volunteers are carefully screened and trained. Extension offers several master volunteer programs that provide training opportunities in gardening and horticulture; food, nutrition, and safety; natural resources management; water supply systems; financial management; and energy conservation.

If you are interested in volunteering, but not sure in what way, contact your local Extension office. They will be happy to help you find a way to share your time and talents.

Hermon Maclin is a Virginia Cooperative Extension Agent, specializing in 4-H youth development, with the Prince George County Extension Office. He can be reached at804-733-2686 ext. 102 or by email at hmaclin@vt.edu .

View post:
Why people do not volunteer - Progress Index

Couple has twins from sperm frozen 26 years ago | The Independent – The Independent

A man who froze his sperm more than two decades before having twins with his partner has claimed a world record.

The Scottishmusician, who did not want to be named, had his sperm frozen when he was 21, before starting chemotherapy treatment for cancer, as doctors warned him he would become infertile.

After his sperm had been kept in cold storage for 26 years and 243 days, his partner underwent in-vitro fertilisation in 2010.

Its quite a big deal for a woman to take that on, he told The Times.

The couple gave birth to a girl and a boy the following year. He was 47, and his partner was 37.

Now 54, he knew he held a world record, but did not want to go public.

The previous world record holder, Alex Powell, had had his sperm frozen for 23 years and the story was reported around the globe. Hewas also about to undergo chemotherapy.

But the musician learnt he could be listed anonymously in Guinness World Records, and he agreed to speak to one newspaper to highlight how long sperm can be frozen and then used to produce healthy children.

For people going through chemotherapy, they should keep hope, he said.

Marco Gaudoin, director of the GCRM medical clinic where the treatment took place, said that frozen sperm could theoretically be stored indefinitely.

Melissa Etheridge reveals that she asked Brad Pitt to donate sperm

The Human Fertilisation and Embryology Authority claims sperm can be frozen for more than 40 years, but that not all sperm survive the process.

It has to be frozen for at least six months before it can be used for treatment, to screen the donor for infections.

See original here:
Couple has twins from sperm frozen 26 years ago | The Independent - The Independent

Pioneering work on stem-cell therapies at UW deserves state support – The Seattle Times

At the University of Washingtons Institute for Stem Cell and Regenerative Medicine, scientists and physicians are manipulating stem cells to heal and restore the function of hearts, eyes, kidneys and other tissues.

IF you have a heart attack, hopefully youll survive. But your body will be forever changed. The worlds best doctors cant undo the damage; instead, drugs and devices will help you live with a heart whose function too often dwindles.

The body cannot replace muscle cells that die in heart attacks maladies that help make heart failure the No. 1 global cause of death and our nations biggest health care expense. These patients face daily medication, decreased energy and, for the lucky 0.1 percent, the ability to qualify for an extraordinarily costly heart transplant and anti-rejection medication that also leaves them more vulnerable to other diseases.

Thanks to medical advances, heart failure has become a chronic condition that people are now managing for decades. The same is true for diabetes, kidney disease and arthritis. But with that longevity comes a tether to drug regimens whose costs rise seemingly at whim.

Dr. Charles Murry is interim director of UW Medicines Institute for Stem Cell and Regenerative Medicine.

These chronic diseases are a major reason that health-care costs hold center stage in Americans consciousness.

Amid our collective uncertainty, medical science offers one path of relief. Specifically, the engineering of human cells and tissues to restore vitality to poorly functioning organs.

The medical conditions named above share a common root not addressed by todays best care: The body is missing a population of cells that do critical work. If we could restore that population, we could cure many chronic diseases.

At the University of Washingtons Institute for Stem Cell and Regenerative Medicine (ISCRM), scientists and physicians are manipulating stem cells to heal and restore the function of hearts, eyes, kidneys and other tissues.

This year, we also seek a first-time investment from our state Legislature.

Weve pioneered techniques to grow unlimited human heart muscle cells in the lab. We were the first to transplant these cells into injured hearts and repair the injury with new tissue growth. UW Medicine will begin first-in-human tests of these cells in Seattle in 2019.

If this one and done treatment prevents heart failure in even the sickest 10 percent of heart-attack patients, our nation could save a staggering $3.5 billion per year in health-care costs. More importantly, these patients will lead longer, healthier, more productive lives.

Other ISCRM scientists are pursuing a gene therapy for muscular dystrophy, a devastating illness that often strikes young boys. The therapy, tested in Labrador puppies that were paraplegic as a result of the same, naturally occurring muscle-wasting disease, had the dogs leaping and frolicking in just weeks. A clinical trial is planned for 2018.

We are similarly probing therapies for cancer, kidney failure, diabetes and Alzheimers. And were doing this with the Northwests entrepreneurial spirit: In the past decade, ISCRM has patented 250+ discoveries with commercial potential and started 20 companies.

Legislatures in at least 11 other states, including California, New York, Wisconsin, Minnesota and Maryland, have invested cumulative billions in regenerative medicine. Most of that funding has gone to university-based research centers like ours.

To this point there has been no state investment in ISCRM. Nevertheless we have built a world-class program with federal grants and private philanthropy. But those dollars come in boom-and-bust cycles, and what we need now is stable funding to maintain competitiveness.

For this reason, the UW seeks $6 million in operating funds from the Legislature, starting with the next biennium, to recruit and retain top scientists, fund promising results at early stages, and train young researchers and clinicians.

We are grateful, at this juncture, that the state Senate included us in its initial budget.

We ask all legislators to invest in the health of our residents and in the promise of what weve accomplished so far. With stem-cell biology, we are ready to rebuild solid tissues like the heart and potentially cure our nations greatest cause of death and health-care expense.

Clinical success will make Washington a destination for heart repair and other regenerative therapies. This race is ours to lose.

Continued here:
Pioneering work on stem-cell therapies at UW deserves state support - The Seattle Times

BRIEF-Beijing Leadman Biochemistry Co Ltd sees Q1 FY 2017 net profit down 10 pct to up 10 pct – Reuters

April 10 Beijing Leadman Biochemistry Co Ltd

* Sees Q1 FY 2017 net profit to decrease by 10 percent to increase by 10 percent, or to be 16.2 million yuan to 19.8 million yuan

* Says Q1 FY 2016 net profit was 18 million yuan

* The reason for the forecast is strengthened the management of customer credit account, reduced bad debts risk and decreased income

Source text in Chinese:goo.gl/9R9L4c

Further company coverage: (Beijing Headline News)

April 10 Denmark will on Wednesday lift an order to keep poultry flocks indoors as the threat of bird flu has lessened, the Ministry of Environment and Food said in a press release on Monday.

* Organigram enters into LoI to acquire Trauma Healing Centers

See original here:
BRIEF-Beijing Leadman Biochemistry Co Ltd sees Q1 FY 2017 net profit down 10 pct to up 10 pct - Reuters